Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Friday: Alpha Natural Resources, Inc.(NYSE:ANR), MannKind Corporation (NASDAQ:MNKD), Seadrill Ltd (NYSE:SDRL), Molycorp Inc (NYSE:MCP)

• Alpha Natural Resources, Inc.(NYSE:ANR), with shares dwindled -8.75% is now trading at $0.840. The Stock is active as 4.95M shares changed hands versus its average volume of 5.09M shares.

• MannKind Corporation (NASDAQ:MNKD), with shares dipped -5.16% is now trading at $5.26. The Stock is active as 4.46M shares changed hands versus its average volume of 6.65M shares.

• Seadrill Ltd (NYSE:SDRL) with shares enhanced 5.23% is now trading at $9.86. The Stock is active as 5.19M shares changed hands versus its average volume of 13.73M shares.

• Molycorp Inc (NYSE:MCP) with shares dropped -4.00% is now trading at $0.350. The Stock is active as 2.82M shares changed hands versus its average volume of 5.77M shares.

Latest NEWS regarding these Stocks are depicted underneath:

Alpha Natural Resources, Inc. (NYSE:ANR)

Alpha Natural Resources, Inc. (ANR), has price to sale ratio of 0.05, however, price to book ratio is 0.07. With recent decline, the year-to-date (YTD) performance reflected a -53.55% decline below last year. During the past month the stocks lose -41.04%, bringing three-month performance to -49.61% and six-month performance to -72.1%. The mean recommendation of analysts for this stock is 3.30. (where 1=Buy, 5=Sale).

Alpha Natural Resources, Inc., together with its auxiliaries, engages in extracting, processing, and marketing steam and metallurgical coal in Kentucky, Pennsylvania, Virginia, West Virginia, and Wyoming.

MannKind Corp. (NASDAQ:MNKD)

A cash shortfall is being faced by MannKind Corp. (MNKD), unless it can settle with debt holders by August.

The alarming issue for the inhaled drug delivery corporation is $100 million in convertible debt that must be repaid or renegotiated by Aug. 15. MannKind’s delicate financial health, a result of years of delays and missteps in developing the inhaled insulin Afrezza, doesn’t leave the corporation with good options for settling with its creditors.

The company is expected to release its next earning report between May 11 - May 15. Mean Recommendation of analysts for the stock is 2.7. (where 1=Buy and 5=Sell).

MannKind Corporation, a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States.

SeaDrill Limited (NYSE:SDRL) the stock volatility for the week is 5.93%, while for the month remained 4.43%.

If we consider EPS growth of the company, then the company indicated the following observations:

The company showed 8.06 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 51.70% and Annual EPS growth for the past 5 years is considered as 22.60%.

The mean recommendation of analysts for this stock is 2.60. (where 1=Buy, 5=Sale).

SeaDrill Limited (SDRL), an offshore drilling contractor, provides offshore drilling services to the oil and gas industry worldwide. The company operates in three segments: Floaters, Jack-up Rigs, and Tender Rigs. The Floaters segment offers services, such as drilling, completion, and maintenance of offshore exploration and production wells under contracts regardingsemi-submersible rigs and drillships for harsh and benign environments in mid, deep, and ultra-deep waters. The Jack-up Rigs segment provides services, counting drilling, completion, and maintenance of offshore exploration and production wells under contracts regardingjack-up rigs for operations in harsh and benign environment. The Tender Rigs segment operates self-erecting tender barges and semi-submersible tender rigs, which are used for production drilling and well maintenance in Southeast Asia and West Africa.

Molycorp, Inc. (NYSE:MCP)

Molycorp, Inc. (MCP), stated higher production volumes in the fourth quarter of 2014 at its Mountain Pass, California rare earth facility, with 1,328 metric tons (“mt”) of rare earth oxide (“REO”) equivalent production. That compares to 1,034 mt in the fourth quarter of 2013 and 691 mt in the third quarter of 2014. Full year 2014 production at Mountain Pass totaled about 4,769 mt, contrast to 3,473 mt in 2013.

The Chlor-Alkali plant at Mountain Pass is performing well and the Corporation is able to produce or purchase sufficient supplies of hydrochloric acid for rare earth production.

Per-unit cash production costs at Mountain Pass declined in the fourth quarter of 2014 to $21.02 per kilogram, a 38% decrease over the third quarter of 2014 costs of $33.80 per kilogram.

The Corporation stated fourth quarter product sales volume of 3,149 mt, a 6% decrease over the third quarter, at an average selling price (“ASP”) of $36.91 per kilogram. For the full year 2014, the Corporation stated sales volume of 13,019 mt, a 1% raise over 2013, at an ASP of about $36.53 per kilogram.

Net proceeds for the quarter were $116.2 million, a 6% decrease from the third quarter. Full year 2014 net proceeds were $475.6 million, a 14% decrease as contrast to 2013.

The Corporation stated a net loss of $1.43 per share for the quarter. The Corporation stated a net loss of $0.39 per share for the quarter on an adjusted non-GAAP basis.

For the full year 2014, the Corporation stated a net loss of $2.70 per share. On an adjusted non-GAAP basis, the Corporation stated a net loss of $1.31 per share for the full year, due largely to impairment of goodwill and other intangible assets and write-offs of certain tangible assets.

Molycorp is the only advanced material manufacturer in the world that both controls a world-class rare earth resource and can produce high-purity, custom engineered rare earth products to meet increasingly demanding customer specifications.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.